The endogenous ghrelin antagonist, LEAP2, accelerates puberty onset in conditions of early obesity

Metabolism: Clinical and Experimental · Published 2026-07-10 · DOI 10.1016/j.metabol.2026.156695

Free full text

Authors (14)

Carmen Torres-Granados, Paul G. Morris, Miguel Ruiz-Cruz, Olga Pomares, Yolanda Guerrero-Ruiz, Esperanza Uceda-Rodríguez, Elvira Rodríguez-Vázquez, Álvaro Aranda-Torrecillas, Carmen Garcés, Francisco Gaytan, Leandro Soriano-Guillén, Allan E. Herbison, Manuel Tena-Sempere, Juan Roa

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Torres-Granados, C., Morris, P., Ruiz-Cruz, M., et al. (2026). The endogenous ghrelin antagonist, LEAP2, accelerates puberty onset in conditions of early obesity. Metabolism: Clinical and Experimental. https://doi.org/10.1016/j.metabol.2026.156695

Related articles

• Dynamic regulation of circulating endotrophin by changes in fat mass in humans · Metabolism: Clinical and Experimental · 2026 · Same journal
• Cytochrome P450 2E1 deficiency alters hepatic mitochondria and impairs liver organoid formation · Metabolism: Clinical and Experimental · 2026 · Same journal
• Metabolomic signatures of type 2 diabetes and mortality: Methodological considerations and unresolved questions · Metabolism: Clinical and Experimental · 2026 · Same journal
• STAU1 fine-tunes adipose thermogenesis by regulating Ucp1 mRNA stability · Metabolism: Clinical and Experimental · 2026 · Same journal
• Gut-liver metabolic and enterohormonal remodeling drives progression from metabolic dysfunction-associated steatotic liver disease to steatohepatitis · Metabolism: Clinical and Experimental · 2026 · Same journal
• Muscle-derived ANXA2 promotes hepatic steatosis by activating SREBP1c-mediated de novo lipogenesis · Metabolism: Clinical and Experimental · 2026 · Same journal
• The effects of acute ketone monoester supplementation on brain insulin responsiveness and cognitive performance: Results of a randomized, double-blind, placebo-controlled crossover trial in older men with overweight · Metabolism: Clinical and Experimental · 2026 · Same journal
• SGLT2 inhibitors and GLP-1 receptor agonists in atrial fibrillation treatment: Clinical evidence and mechanistic insights · Metabolism: Clinical and Experimental · 2026 · Same journal
• Data leakage and overadjustment bias in proteomic prediction models of mortality among cardiovascular-kidney-metabolic syndrome stage 0–3 · Metabolism: Clinical and Experimental · 2026 · Same journal
• Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses · Metabolism: Clinical and Experimental · 2026 · Same journal